Abstract:BACKGROUND AND AIMS: Infants with Down syndrome (DS) or Trisomy 21, are at high risk for developing pulmonary arterial hypertension (PAH), but mechanisms that increase susceptibility are poorly understood. Laboratory studies have shown that early disruption of angiogenesis during development impairs vascular and alveolar growth and causes PAH. Human chromosome 21 encodes known anti-angiogenic factors, including collagen18a1 (endostatin, ES), ß-amyloid peptide (BAP) and Down Syndrome Critical Region 1 (DSCR-1). Therefore, we hypothesized that fetal lungs from subjects with DS are characterized by early over-expression of anti-angiogenic factors and have abnormal lung vascular growth in utero.METHODS: Human fetal lung tissue from DS and non-DS subjects were obtained from a biorepository. Quantitative reverse transcriptase PCR (qRT-PCR) was performed to assay 84 angiogenesis-associated genes and individual qRT-PCR was performed for ES, amyloid protein precursor (APP) and DSCR1. Western blot analysis (WBA) was used to assay lung ES, APP and DSCR-1 protein contents. Lung vessel density and wall thickness were determined by morphometric analysis.RESULTS: The angiogenesis array identified up-regulation of three anti-angiogenic genes: COL18A1 (ES), COL4A3 (tumstatin) and TIMP3 (tissue inhibitor of metallopeptidase 3) in DS lungs. Single qRT-PCR and WBA showed striking elevations of ES and APP mRNA (p = 0.022 and p = 0.001) and protein (p = 0.040 and p = 0.002; respectively). Vessel density was reduced (p = 0.041) and vessel wall thickness was increased in DS lung tissue (p = 0.033) when compared to non-DS subjects.CONCLUSIONS: We conclude that lung anti-angiogenic factors, including COL18A1 (ES), COL4A3, TIMP3 and APP are over-expressed and fetal lung vessel growth is decreased in subjects with DS. We speculate that increased fetal lung anti-angiogenic factor expression due to trisomy 21 impairs lung vascular growth and signaling, which impairs alveolarization and contributes to high risk for PAH during infancy.

Trisomy 21 Alters Cell Proliferation and Migration of iPSC-Derived Cardiomyocytes on Type VI Collagen

Increased endothelial sclerostin caused by elevated DSCAM mediates multiple trisomy 21 phenotypes

Trisomy 21-driven metabolite alterations are linked to cellular injuries in Down syndrome

Interferon hyperactivity impairs cardiogenesis in Down syndrome via downregulation of canonical Wnt signaling

Increased Lung Expression of Anti-Angiogenic Factors in Down Syndrome: Potential Role in Abnormal Lung Vascular Growth and the Risk for Pulmonary Hypertension

Genetic analysis of Down syndrome-associated heart defects in mice

Susceptibility to Heart Defects in Down Syndrome Is Associated with Single Nucleotide Polymorphisms in HAS 21 Interferon Receptor Cluster and VEGFA Genes

Migration deficits of the neural crest caused by CXADR triplication in a human Down syndrome stem cell model

Transcriptional consequences of trisomy 21 on neural induction

What people with Down Syndrome can teach us about cardiopulmonary disease

The burden of trisomy 21 disrupts the proteostasis network in Down syndrome

Chromosomal and cellular therapeutic approaches for Down syndrome: A research update

Increased dosage of DYRK1A leads to congenital heart defects in a mouse model of Down syndrome

Single cell atlas of trisomy 21 cerebral cortex

Consequences of trisomy 21 for brain development in Down syndrome

Deficits in Human Trisomy 21 Ipscs and Neurons

Single‐cell landscape analysis reveals systematic senescence in mammalian Down syndrome

DYRK1A gene linked to heart defects in Down syndrome

ALK2 mutation in a patient with Down's syndrome and a congenital heart defect

Single-cell RNA Sequencing of Neural Stem Cells Derived from Human Trisomic Ipscs Reveals the Abnormalities During Neural Differentiation of Down Syndrome.

Human Chromosome 21 Orthologous Region on Mouse Chromosome 17 is a Major Determinant of Down Syndrome-Related Developmental Cognitive Deficits.